Hepatitis Viruses and Liver Transplantation. Evolving Trends in Antiviral Management

Clinics in Liver Disease

Volumn 18, Issue 3, 2014, Pages 575-601

  Verna, Elizabeth C ^a  

^a Division of Digestive and Liver Diseases Center for Liver Disease and Transplantation Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Antiviral therapy; HBV; HCV; HEV; Liver transplant

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY;

ANTIVIRAL THERAPY; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER BIOPSY; LIVER TRANSPLANTATION; ORGAN DONOR; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; ADVERSE EFFECTS; COMPLICATION; DONOR SELECTION; END STAGE LIVER DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HOSPITAL ADMISSION; TRENDS;

ANTIVIRAL AGENTS; DONOR SELECTION; END STAGE LIVER DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS E; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER TRANSPLANTATION; RECURRENCE; WAITING LISTS;

EID: 84903983346     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.05.002     Document Type: Review

References (149)

1. Thuluvath P.J., Guidinger M.K., Fung J.J., et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010, 10:1003-1019.
2. Picciotto F.P., Tritto G., Lanza A.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. JHepatol 2007, 46:459-465.
3. Berenguer M., Palau A., Aguilera V., et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008, 8:679-687.
4. Bizollon T., Pradat P., Mabrut J.Y., et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005, 5:1909-1913.
5. Recommendations for testing, managing, and treating hepatitis C. Available at: Accessed March 3, 2014. http://wwwhcvguidelinesorg.
6. Berenguer M., Prieto M., Rayon J.M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852-858.
7. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18:29-37.
8. Maluf D.G., Edwards E.B., Stravitz R.T., et al. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl 2009, 15:592-599.
9. Lai J.C., O'Leary J.G., Trotter J.F., et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012, 18:532-538.
10. Lai J.C., Verna E.C., Brown R.S., et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011, 54(2):418-424.
11. Verna E.C., Valadao R., Farrand E., et al. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl 2012, 18:461-467.
12. Saxena V., Lai J.C., O'Leary J.G., et al. Donor-recipient race mismatch in African-American liver transplant patients with chronic hepatitis C. Liver Transpl 2012, 18(5):524-531.
13. Verna E.C., De Martin E., Burra P., et al. The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation. Am J Transplant 2009, 9:1398-1405.
14. Berenguer M., Prieto M., Cordoba J., et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. JHepatol 1998, 28:756-763.
15. Sheiner P.A., Schwartz M.E., Mor E., et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995, 21:30-34.
16. Berenguer M., Aguilera V., Prieto M., et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. JHepatol 2006, 44:717-722.
17. Irish W.D., Arcona S., Bowers D., et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011, 11:1676-1685.
18. Watt K.D., Dierkhising R., Heimbach J.K., et al. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012, 18:1029-1036.
19. Bahra M., Neumann U.I., Jacob D., et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005, 5:406-411.
20. Charlton M.R., Thompson A., Veldt B.J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53:317-324.
21. Dhillon N., Walsh L., Kruger B., et al. Asingle nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. JHepatol 2010, 53:67-72.
22. do O.N., Eurich D., Schmitz P., et al. A7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection. Liver Transpl 2012, 18:298-304.
23. Berenguer M., Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. JHepatol 2013, 58(5):1028-1041.
24. Adebajo C.O., Talwalkar J.A., Poterucha J.J., et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012, 18:323-331.
25. Crespo G., Lens S., Gambato M., et al. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. Am J Transplant 2014, 14:375-383.
26. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
27. Everson G.T., Terrault N.A., Lok A.S., et al. Arandomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013, 57:1752-1762.
28. Hezode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. JHepatol 2013, 59(3):434-441.
29. Colombo M., Fernandez I., Abdurakhmanov D., et al. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2013, [Epub ahead of print]. 10.1136/gutjnl-2013-305667.
30. Ogawa E., Furusyo N., Nakamuta M., et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013, 38:1076-1085.
31. Verna E.C., Shetty K., Lukose T., et al. High post-transplant virologic response in hepatitis C virus infected patients treated with pre-transplant protease inhibitor-based triple therapy. Liver Int 2014 Jun 6, 10.1111/liv.12616.
32. Curry M.P., Forns X., Chung R.T., et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013, 58:314S-315S.
33. Bzowej N., Nelson D.R., Terrault N.A., et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011, 17:528-538.
34. Crespo G., Carrion J.A., Coto-Llerena M., et al. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. JGastroenterol 2013, 48(6):762-769.
35. Berenguer M., Aguilera V., Rubin A., et al. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. JHepatol 2012, 56:1310-1316.
36. Wang C.S., Ko H.H., Yoshida E.M., et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006, 6:1586-1599.
37. Garg V., van Heeswijk R., Lee J.E., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54:20-27.
38. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56:1622-1630.
39. O'Leary J.G., McKenna G.J., Klintmalm G.B., et al. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 2013, 19:463-465.
40. Coilly A., Roche B., Dumortier J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. JHepatol 2014, 60:78-86.
41. Burton J.R., O'Leary J.G., Verna E.C., et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014 May 3, [Epub ahead of print]. 10.1016/j.jhep.2014.04.037.
42. Faisal N., Renner E.L., Bilodeau M., et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicenter experience. Hepatology 2013, 58:238A.
43. Brown K.A., Fontana R.J., Russo M.W., et al. Twice-daily Telaprevir in combination with Pefinterferon Alpha-2a/Ribavirin in genotype 1 HCV Liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter REFRESH study. Hepatology 2013, 58:209A.
44. Samuel D., Charlton M., Gane E., et al. Sofosbuvir and Ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. JHepatol 2014, 60:S499.
45. Forns X., Prieto M., Charlton M., et al. Sofosbuvir compassionate use progran forpatients wtih severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. JHepatol 2014, 60:S26.
46. Fontana R.J., Hughes E.A., Appelman H., et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012, 18:1053-1059.
47. Fontana R.J., Hughes E.A., Bifano M., et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013, 13:1601-1605.
48. Pellicelli A.M., Lionetti R., Montalbano M., et al. Sofosbuvir and Daclatasvir for recurrent hepatitis C after liver transplantation: potent antiviral activity but lack of clinical benefit if treatment is given too late. JHepatol 2014, 60:S532.
49. Jacobson I.M., Ghalib R.M., Rodriguez-Torres M. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013, 58.
50. Singal A.K., Guturu P., Hmoud B., et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013, 95:755-760.
51. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54:91-100.
52. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349-360.
53. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419-1427.
54. Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
55. Campsen J., Zimmerman M., Trotter J., et al. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl 2013, 19:1020-1029.
56. Samuel D., Bismuth A., Mathieu D., et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991, 337:813-815.
57. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 24:1327-1333.
58. McGory R.W., Ishitani M.B., Oliveira W.M., et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996, 61:1358-1364.
59. Konig V., Hopf U., Neuhaus P., et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994, 58:553-559.
60. Muller R., Gubernatis G., Farle M., et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. JHepatol 1991, 13:90-96.
61. Sawyer R.G., McGory R.W., Gaffey M.J., et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998, 227:841-850.
62. Cholongitas E., Papatheodoridis G.V. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013, 13:353-362.
63. Fox A.N., Terrault N.A. The option of HBIG-free prophylaxis against recurrent HBV. JHepatol 2012, 56:1189-1197.
64. Loomba R., Rowley A.K., Wesley R., et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008, 6:696-700.
65. Perrillo R., Buti M., Durand F., et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013, 19:887-895.
66. Wesdorp D.J., Knoester M., Braat A.E., et al. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. JClin Virol 2013, 58:67-73.
67. Na G.H., Kim D.G., Han J.H., et al. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation. JGastroenterol Hepatol 2014, 29:151-156.
68. Gao Y.J., Zhang M., Jin B., et al. Aclinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. JGastroenterol Hepatol 2014, 29(3):554-560.
69. Tanaka T., Renner E.L., Selzner N., et al. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol 2014, 28:41-44.
70. Gane E.J., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132:931-937.
71. Angus P.W., Patterson S.J., Strasser S.I., et al. Arandomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
72. Degertekin B., Han S.H., Keeffe E.B., et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010, 10:1823-1833.
73. Teperman L.W., Poordad F., Bzowej N., et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013, 19:594-601.
74. Angelico M., Di Paolo D., Trinito M.O., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002, 35:176-181.
75. Sanchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000, 31:496-501.
76. Rosenau J., Hooman N., Hadem J., et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007, 13:367-373.
77. Klein C.G., Cicinnati V., Schmidt H., et al. Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study. Ann Transplant 2013, 18:677-684.
78. Wadhawan M., Gupta S., Goyal N., et al. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl 2013, 19:1030-1035.
79. Fung J., Chan S.C., Cheung C., et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013, 108:942-948.
80. Terrault N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?. Am J Gastroenterol 2013, 108:949-951.
81. Marzano A., Gaia S., Ghisetti V., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005, 11:402-409.
82. Chazouilleres O., Mamish D., Kim M., et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994, 343:142-146.
83. Dickson R.C., Everhart J.E., Lake J.R., et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997, 113:1668-1674.
84. Bohorquez H.E., Cohen A.J., Girgrah N., et al. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transpl 2013, 19:611-618.
85. Wachs M.E., Amend W.J., Ascher N.L., et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59:230-234.
86. Prieto M., Gomez M.D., Berenguer M., et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51-58.
87. Munoz S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002, 8:S82-S87.
88. Manzarbeitia C., Reich D.J., Ortiz J.A., et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8:556-561.
89. Barcena R., Moraleda G., Moreno J., et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006, 12:2070-2074.
90. Yu A.S., Vierling J.M., Colquhoun S.D., et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001, 7:513-517.
91. Chang M.S., Olsen S.K., Pichardo E.M., et al. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl 2012, 18:834-838.
92. Abdelmalek M.F., Pasha T.M., Zein N.N., et al. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003, 9:1253-1257.
93. Thomas D.L., Yarbough P.O., Vlahov D., et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. JClin Microbiol 1997, 35:1244-1247.
94. Kuniholm M.H., Purcell R.H., McQuillan G.M., et al. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. JInfect Dis 2009, 200:48-56.
95. Kamar N., Rostaing L., Legrand-Abravanel F., et al. How should hepatitis E virus infection be defined in organ-transplant recipients?. Am J Transplant 2013, 13:1935-1936.
96. Pischke S., Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem?. Minerva Gastroenterol Dietol 2010, 56:121-128.
97. Kamar N., Weclawiak H., Guilbeau-Frugier C., et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012, 93:617-623.
98. Lhomme S., Abravanel F., Dubois M., et al. Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. JVirol 2012, 86:10006-10014.
99. Kamar N., Garrouste C., Haagsma E.B., et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011, 140:1481-1489.
100. Pischke S., Suneetha P.V., Baechlein C., et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010, 16:74-82.
101. Kamar N., Mansuy J.M., Cointault O., et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008, 8:1744-1748.
102. Kamar N., Selves J., Mansuy J.M., et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. NEngl J Med 2008, 358:811-817.
103. Gerolami R., Moal V., Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. NEngl J Med 2008, 358:859-860.
104. Hering T., Passos A.M., Perez R.M., et al. Past and current hepatitis E virus infection in renal transplant patients. JMed Virol 2014, 86(6):948-953.
105. Kenfak-Foguena A., Schoni-Affolter F., Burgisser P., et al. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 2011, 17:1074-1078.
106. Kaba M., Richet H., Ravaux I., et al. Hepatitis E virus infection in patients infected with the human immunodeficiency virus. JMed Virol 2011, 83:1704-1716.
107. Jagjit Singh G.K., Ijaz S., Rockwood N., et al. Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV. JInfect 2013, 66:103-106.
108. Mateos-Lindemann M.L., Diez-Aguilar M., Galdamez A.L., et al. Patients infected with HIV are at high-risk for hepatitis E virus infection in Spain. JMed Virol 2014, 86:71-74.
109. Colson P., Dhiver C., Poizot-Martin I., et al. Acute and chronic hepatitis E in patients infected with human immunodeficiency virus. JViral Hepat 2011, 18:227-228.
110. Motte A., Roquelaure B., Galambrun C., et al. Hepatitis E in three immunocompromized children in southeastern France. JClin Virol 2012, 53:162-166.
111. le Coutre P., Meisel H., Hofmann J., et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 2009, 58:699-702.
112. Abravanel F., Mansuy J.M., Huynh A., et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. JClin Virol 2012, 54:152-155.
113. Haagsma E.B., Riezebos-Brilman A., van den Berg A.P., et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 2010, 16:474-477.
114. Kamar N., Rostaing L., Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. Semin Liver Dis 2013, 33:62-70.
115. Kamar N., Rostaing L., Abravanel F., et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010, 139:1612-1618.
116. Chaillon A., Sirinelli A., De Muret A., et al. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. JHeart Lung Transplant 2011, 30:841-843.
117. Mallet V., Nicand E., Sultanik P., et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010, 153:85-89.
118. Kamar N., Rostaing L., Abravanel F., et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010, 50:e30-e33.
119. Pischke S., Hardtke S., Bode U., et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013, 33:722-726.
120. Kamar N., Izopet J., Tripon S., et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. NEngl J Med 2014, 370:1111-1120.
121. Kamar N., Abravanel F., Selves J., et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010, 89:353-360.
122. Aggarwal R. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol 2013, 10:24-33.
123. Abravanel F., Chapuy-Regaud S., Lhomme S., et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. JClin Virol 2013, 58:624-628.
124. Bendall R., Ellis V., Ijaz S., et al. Acomparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. JMed Virol 2010, 82:799-805.
125. Mast E.E., Alter M.J., Holland P.V., et al. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology 1998, 27:857-861.
126. Rossi-Tamisier M., Moal V., Gerolami R., et al. Discrepancy between anti-hepatitis E virus immunoglobulin G prevalence assessed by two assays in kidney and liver transplant recipients. JClin Virol 2013, 56:62-64.
127. Baylis S.A., Hanschmann K.M., Blumel J., et al. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. JClin Microbiol 2011, 49:1234-1239.
128. Baylis S.A., Blumel J., Mizusawa S., et al. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis 2013, 19:729-735.
129. Haagsma E.B., Niesters H.G., van den Berg A.P., et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009, 15:1225-1228.
130. Hoerning A., Hegen B., Wingen A.M., et al. Prevalence of hepatitis E virus infection in pediatric solid organ transplant recipients-a single-center experience. Pediatr Transplant 2012, 16:742-747.
131. Legrand-Abravanel F., Kamar N., Sandres-Saune K., et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis 2011, 17:30-37.
132. Pas S.D., de Man R.A., Mulders C., et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 2012, 18:869-872.
133. Buti M., Cabrera C., Jardi R., et al. Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?. Liver Transpl 2010, 16:106-107. [author reply: 108].
134. Kamar N., Bendall R.P., Peron J.M., et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011, 17:173-179.
135. Del Bello A., Arne-Bes M.C., Lavayssiere L., et al. Hepatitis E virus-induced severe myositis. JHepatol 2012, 57:1152-1153.
136. Taton B., Moreau K., Lepreux S., et al. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. Transpl Infect Dis 2013, 15:E211-E215.
137. Wang Y., Zhou X., Debing Y., et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014, 146(7):1775-1783.
138. Kamar N., Legrand-Abravanel F., Izopet J., et al. Hepatitis E virus: what transplant physicians should know. Am J Transplant 2012, 12:2281-2287.
139. Unzueta A., Rakela J. Hepatitis E infection in liver transplant recipients. Liver Transpl 2014, 20(1):15-24.
140. Schlosser B., Stein A., Neuhaus R., et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. JHepatol 2012, 56:500-502.
141. Thomas R.M., Brems J.J., Guzman-Hartman G., et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003, 9:905-915.
142. Forns X., Garcia-Retortillo M., Serrano T., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. JHepatol 2003, 39:389-396.
143. Carrion J.A., Martinez-Bauer E., Crespo G., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. JHepatol 2009, 50:719-728.
144. Mathias A., Cornpropst M., Clemons D. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (CG-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers. Hepatology 2012, 56(Suppl 1):1063A-1064A.
145. Ouwerkerk-Mahadevan S., Sinmion A., Mortier S. No clinically significant interaction between the Investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. Hepatology 2012, 56(Suppl 1):231A.
146. Kwo P., Mantry P., Coakley E., et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/R/ABT-267+ ABT-333+ ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. JHepatol 2014, 60:S47.
147. Haagsma E.B., van den Berg A.P., Porte R.J., et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008, 14:547-553.
148. Halac U., Beland K., Lapierre P., et al. Chronic hepatitis E infection in children with liver transplantation. Gut 2012, 61:597-603.
149. Junge N., Pischke S., Baumann U., et al. Results of single-center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin. Pediatr Transplant 2013, 17:343-347.